Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2.

@article{Heijde2007InfliximabIP,
  title={Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2.},
  author={D{\'e}sir{\'e}e Mfm van der Heijde and Arthur J Kavanaugh and Dafna D Gladman and Christian E. Antoni and Gerald G. Krueger and C. Guzzo and Bei Zhou and Lisa T Dooley and Kurt de Vlam and Piet P. Geusens and Charles A Birbara and Dr. Gustav Halter and Anna M Beutler},
  journal={Arthritis and rheumatism},
  year={2007},
  volume={56 8},
  pages={2698-707}
}
OBJECTIVE To evaluate the effect of infliximab on progression of structural damage over 1 year in patients with active psoriatic arthritis (PsA) enrolled in the Induction and Maintenance Psoriatic Arthritis Clinical Trial 2. METHODS In this double-blind, placebo-controlled study, 200 patients with active PsA were randomly assigned (1:1 ratio) to receive infusions of infliximab (5 mg/kg) or placebo at weeks 0, 2, and 6, and every 8 weeks thereafter through week 54. At week 24, patients… CONTINUE READING